The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors

The BCR-ABL1 fusion gene is the driver oncogene in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). The introduction of tyrosine kinase inhibitors (TKIs) targeting the ABL kinase (such as imatinib) has dramatically improved survival of CML...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahjat, Mahnoush, de Wilde, Guus, van Dam, Tijmen, Maas, Chiel, Bloedjes, Timon, Bende, Richard J., van Noesel, Carel J.M., Luijks, Dieuwertje M., Eldering, Eric, Kersten, Marie José, Guikema, Jeroen E.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738521/
https://www.ncbi.nlm.nih.gov/pubmed/31349760
http://dx.doi.org/10.1080/15384101.2019.1646068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738521/
https://www.ncbi.nlm.nih.gov/pubmed/31349760
http://dx.doi.org/10.1080/15384101.2019.1646068

Ejemplares similares